SG11201908079SA - Recombinant host cell with altered membrane lipid composition - Google Patents

Recombinant host cell with altered membrane lipid composition

Info

Publication number
SG11201908079SA
SG11201908079SA SG11201908079SA SG11201908079SA SG 11201908079S A SG11201908079S A SG 11201908079SA SG 11201908079S A SG11201908079S A SG 11201908079SA SG 11201908079S A SG11201908079S A SG 11201908079SA
Authority
SG
Singapore
Prior art keywords
international
host cell
pct
gmbh
protein
Prior art date
Application number
Inventor
Karlheinz Grillitsch
Guenther Daum
Andreas Grutsch
Original Assignee
Boehringer Ingelheim Rcv Gmbh
Validogen Gmbh
Lonza Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Rcv Gmbh, Validogen Gmbh, Lonza Ag filed Critical Boehringer Ingelheim Rcv Gmbh
Publication of SG11201908079SA publication Critical patent/SG11201908079SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 04 October 2018 (04.10.2018) W I PO I PCT 011101 V III o Ho VIII VIII om° VII IE (10) International Publication Number WO 2018/178126 Al (51) International Patent Classification: C12N 15/63 (2006.01) Cl 2P 21/00 (2006.01) (21) International Application Number: PCT/EP2018/057853 (22) International Filing Date: 28 March 2018 (28.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 17163588.1 29 March 2017 (29.03.2017) EP (71) Applicants: BOEHRINGER INGELHEIM RCV GMBH & CO KG [AT/AT]; Dr.-Boehringer-Gasse 5-11, 1121 Wien (AT). SANDOZ AG [CH/CH]; Lichtstrasse 35, 4056 Basel (CH). VTU TECHNOLOGY GMBH [AT/AT]; Parkring 18, 8074 Grambach (AT). BIOMIN HOLDING GMBH [AT/AT]; Industriestrasse 21, 3130 Herzogenburg (AT). LONZA LTD [CH/CH]; Lonzas- trasse, 3930 Visp (CH). (72) Inventors: GRILLITSCH, Karlheinz; Buxersiedlung 30, 9470 St. Paul/Lav (AT). DAUM, Guenther; Peterstal- strasse 36b, 8042 Graz (AT). GRUTSCH, Andreas; Hofweg 2, 8046 Stattegg (AT). (74) Agent: WEINZIERL, Gerhard et al.; Schiweck Weinzierl Koch, European Patent Attorneys, Landsberger Strasse 98, 80339 Munich (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 1-1 EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, 1-1 00 N 1-1 00 1-1 O C TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) (54) Title: RECOMBINANT HOST CELL WITH ALTERED MEMBRANE LIPID COMPOSITION (57) : The present invention is in the field of recombinant biotechnology, in particular in the field of protein expression. The invention generally relates to a method of expressing a protein of interest (POI) from a host cell. The invention relates particularly to improving a host cell's capacity to express and/or secrete a protein of interest and use of the host cell for protein expression. The invention also relates to cell culture technology, and more specifically to culturing cells to produce desired molecules for medical purposes or food products.
SG11201908079S 2017-03-29 2018-03-28 Recombinant host cell with altered membrane lipid composition SG11201908079SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17163588 2017-03-29
PCT/EP2018/057853 WO2018178126A1 (en) 2017-03-29 2018-03-28 Recombinant host cell with altered membrane lipid composition

Publications (1)

Publication Number Publication Date
SG11201908079SA true SG11201908079SA (en) 2019-10-30

Family

ID=58464254

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201908079S SG11201908079SA (en) 2017-03-29 2018-03-28 Recombinant host cell with altered membrane lipid composition
SG10202110774QA SG10202110774QA (en) 2017-03-29 2018-03-28 Recombinant host cell with altered membrane lipid composition

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202110774QA SG10202110774QA (en) 2017-03-29 2018-03-28 Recombinant host cell with altered membrane lipid composition

Country Status (9)

Country Link
US (2) US11479798B2 (en)
EP (1) EP3601575A1 (en)
JP (1) JP7189145B2 (en)
KR (1) KR20190140939A (en)
CN (1) CN110612352A (en)
AU (1) AU2018241920B2 (en)
CA (1) CA3056920A1 (en)
SG (2) SG11201908079SA (en)
WO (1) WO2018178126A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110951635A (en) * 2019-12-17 2020-04-03 江南大学 Method for regulating saccharomyces cerevisiae cell membrane phospholipid to resist salt stress
CN112430611A (en) * 2020-11-30 2021-03-02 华南理工大学 Optimized zearalenone degrading enzyme ZHD-P encoding gene, recombinant thallus, surface display system and application
CN115160420B (en) * 2022-06-24 2023-06-02 西南大学 Pichia glabra SCP (SCP) secretion protein and application thereof
CN117777276A (en) * 2024-02-23 2024-03-29 北京国科星联科技有限公司 Method for promoting secretion expression of human lactoferrin by kluyveromyces marxianus

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4546082A (en) 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins
US4760025A (en) 1984-05-29 1988-07-26 Genencor, Inc. Modified enzymes and methods for making same
US4601893A (en) 1984-02-08 1986-07-22 Pfizer Inc. Laminate device for controlled and prolonged release of substances to an ambient environment and method of use
GB8726953D0 (en) 1987-11-18 1987-12-23 Delta Biotechnology Ltd Yeast expression system
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
HU218717B (en) 1989-03-17 2000-11-28 E. I. Du Pont De Nemours And Co. Gene fragments from plants enhancing the production of nucleic acids, and process for producing them
DE4027453A1 (en) 1990-08-30 1992-03-05 Degussa NEW PLASMIDES FROM CORYNEBACTERIUM GLUTAMICUM AND DERIVED PLASMIDE VECTORS
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
DE4343591A1 (en) 1993-12-21 1995-06-22 Evotec Biosystems Gmbh Process for the evolutionary design and synthesis of functional polymers based on shape elements and shape codes
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
DE4440118C1 (en) 1994-11-11 1995-11-09 Forschungszentrum Juelich Gmbh Gene expression in coryneform bacteria regulating DNA
GB9515941D0 (en) 1995-08-03 1995-10-04 Zeneca Ltd DNA constructs
GB9516241D0 (en) 1995-08-08 1995-10-11 Zeneca Ltd Dna constructs
JPH10229891A (en) 1997-02-20 1998-09-02 Mitsubishi Rayon Co Ltd Production of malonic acid derivative
EP0973918B1 (en) 1997-04-11 2008-06-11 DSM IP Assets B.V. Yeast cells comprising at least two copies of a desired gene integrated into the chromosomal genome at more than one non-ribosomal rna encoding domain, particularly with kluyveromyces
US7314712B2 (en) 2001-07-27 2008-01-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Systems for in vivo site-directed mutagenesis using oligonucleotides
DE10219203A1 (en) * 2002-04-29 2003-11-13 Basf Plant Science Gmbh Process for the production of polyunsaturated fatty acids in plants
US7470532B2 (en) * 2005-10-19 2008-12-30 E.I. Du Pont De Nemours And Company Mortierella alpina C16/18 fatty acid elongase
CN101605887B (en) * 2006-05-16 2012-09-05 协和发酵麒麟株式会社 High secretion production method of protein
NZ580043A (en) 2007-03-02 2012-04-27 Boehringer Ingelheim Pharma Improvement of protein production through increased expression of mutated start domain protein cert
AU2008241061A1 (en) 2007-04-20 2008-10-30 Polymun Scientific Immunbiologische Forschung Gmbh Yeast expression systems
CA2802775C (en) 2010-06-17 2019-09-24 Vib Vzw Increased protein expression through increased membrane formation
BR112013000219B1 (en) 2010-07-05 2021-06-01 Lonza Ltd METHOD FOR THE PRODUCTION OF A RECOMBINANT POI, A HIGH-PRODUCING CELL LINE AND A HIGH-PRODUCING CELL CULTURE, METHODS FOR INCREASE YIELD AND PROLONGING THE PRODUCTION PHASE OF A POL
WO2012071439A1 (en) * 2010-11-22 2012-05-31 The Regents Of The University Of California Host cells and methods for producing diacid compounds
JP6295512B2 (en) 2012-03-15 2018-03-20 株式会社豊田中央研究所 Method for producing foreign gene expression product in yeast, expression regulator in yeast and use thereof
MY195138A (en) * 2012-10-15 2023-01-11 Genomatica Inc Microorganisms and Methods for Production of Specific Length Fatty Alcohols and Related Compounds
AU2015248815B2 (en) * 2014-04-17 2021-07-08 Boehringer Ingelheim Rcv Gmbh & Co Kg Recombinant host cell engineered to overexpress helper proteins
KR102291978B1 (en) 2014-04-17 2021-08-23 베링거 인겔하임 에르체파우 게엠베하 운트 코 카게 Recombinant host cell for expressing protein of interest
KR102311681B1 (en) 2015-07-28 2021-10-12 삼성전자주식회사 Yeast cell resistant to acid, method for producing an organic acid using the same, and method for producing the same

Also Published As

Publication number Publication date
US20230257792A1 (en) 2023-08-17
CA3056920A1 (en) 2018-10-04
JP7189145B2 (en) 2022-12-13
KR20190140939A (en) 2019-12-20
AU2018241920A1 (en) 2019-09-19
CN110612352A (en) 2019-12-24
WO2018178126A1 (en) 2018-10-04
US20210301313A1 (en) 2021-09-30
EP3601575A1 (en) 2020-02-05
US11479798B2 (en) 2022-10-25
AU2018241920B2 (en) 2022-04-21
SG10202110774QA (en) 2021-11-29
JP2020515261A (en) 2020-05-28

Similar Documents

Publication Publication Date Title
SG11201903454VA (en) Immunologically discernible cell surface variants for use in cell therapy
SG11201908079SA (en) Recombinant host cell with altered membrane lipid composition
SG11201805320XA (en) Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201806002SA (en) Methods for extending the replicative capacity of somatic cells during an ex vivo cultivation process
SG11201807378SA (en) Trans-replicating rna
SG11201907298WA (en) Methods and compositions for gene transfer across the vasculature
SG11201810780XA (en) Single use bioreactor
SG11201908280SA (en) "chimeric molecules and uses thereof"
SG11201906297QA (en) Nucleic acids encoding crispr-associated proteins and uses thereof
SG11201807188VA (en) Modified cells for immunotherapy
SG11201906161VA (en) Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201804070XA (en) Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
SG11201900447SA (en) Methods and compositions for modifying genomic dna
SG11201806340YA (en) Zika virus vaccine
SG11201901206SA (en) Trimer stabilizing hiv envelope protein mutations
SG11201407866XA (en) Method for expression of heterologous proteins using a recombinant negative-strand rna virus vector
SG11201808592PA (en) Method for selection of high m6p recombinant proteins
SG11201807041PA (en) Improved preparations of adult liver progenitor cells
SG11201803642WA (en) Bacteria-based protein delivery
SG11201908657VA (en) Engineered gram-negative endolysins
SG11201807881VA (en) Compositions and methods for making antibodies based on use of an expression-enhancing locus
SG11201806392XA (en) Personalized delivery vector-based immunotherapy and uses thereof
SG11201901684XA (en) Anti-dengue virus antibodies, polypeptides containing variant fc regions, and methods of use